Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →Filing growth compares 2021 (210 records) with 2024 (143) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 8,130 records in scope (CR5), not by the ranked leaders only.
This dataset tracks patent families addressing oligonucleotide synthesis and adjacent process controls: phosphoramidite chemistry, solid-support synthesis, coupling efficiency, detritylation control, acetonitrile consumption, column scale and deprotection conditions. It spans records published between 2015 and mid-2026, a window that captures the shift from small-scale therapeutic oligonucleotide synthesis toward the process-engineering concerns that matter at manufacturing scale. Records are drawn from filings at the United States, EPO, WIPO/PCT, Australia, Canada and AT receiving offices.
Because a single family can carry several IPC classes, and because assignees continuation-file at different rates across jurisdictions, family-level counts give a fairer read of where claim density actually sits than raw document totals do. The picture below uses that lens throughout.
Pick a task. Every answer cites the patents behind it.
Two views of the same 8,130 records: how filing activity has moved year over year, and which IPC subclasses carry the claim weight.
Filings rose to a peak of 247 in 2018, then eased; the 2021-to-2024 span shows a 32% decline (210 to 143), the last three-year comparison the dataset supports before the publication lag makes 2025 and 2026 numbers provisional. Treat the 2026 figure of 22 as a floor, not a signal that filing has stopped.
C12N (49.2%) and C07H (45.2%) dominate, consistent with a field still centred on the genetic-engineering and nucleic-acid chemistry itself. A61K (44.5%) and C12Q (25.0%) show the therapeutic-formulation and testing layers are well populated too, while C12P at 10.1% marks fermentation and enzymatic synthesis routes as comparatively open.
Shares are the percentage of the 8,130 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
This page is one run against one query. Ask Eureka your own question about oligonucleotide manufacturing process and every answer comes back with the patent numbers behind it.
Try EurekaMethods of synthesizing oligonucleotides with high coupling efficiency (>99.5%) are provided, alongside purification methods, instrumentation configurations, and design/assembly methods optimised for building longer polynucleotides from shorter oligonucleotide segments, including codon-bias-aware design for host expression.Filed by DNA Twopointo, Inc.; published 2009-12-24.


| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5034506A | Uncharged morpholino-based polymers having achiral intersubunit linkages | 6,574 |
| 2 | US5744305A | Arrays of materials attached to a substrate | 4,474 |
| 3 | US5185444A | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages | 3,804 |
| 4 | US5519134A | Pyrrolidine-containing monomers and oligomers | 3,307 |
| 5 | US5608046A | Conjugated 4'-desmethyl nucleoside analog compounds | 3,064 |
| 6 | US5525711A | Pteridine nucleotide analogs as fluorescent DNA probes | 2,947 |
| 7 | US5585481A | Linking reagents for nucleotide probes | 2,857 |
| 8 | US5681941A | Substituted purines and oligonucleotide cross-linking | 2,747 |
| 9 | US5367066A | Oligonucleotides with selectably cleavable and/or abasic sites | 2,704 |
| 10 | US5596091A | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides | 2,648 |
Citation counts accumulate over time, so older morpholino- and array-chemistry patents dominate this list; that reflects influence within the searched corpus, not which claims matter for a filing decision today.
Each row carries its publication number; clicking a row searches Eureka by that number.
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Three figures from this dataset carry direct implications for where new claims are likely to clear and where they are likely to collide with existing art.
Five assignees hold just over a quarter of all records in scope, and the top ten combined reach 36.2%. That still leaves nearly two-thirds of the field spread across a ranked list of 100 companies with a pronounced long tail — concentration at the top does not mean the rest of the space is empty.
The peak year was 2018 at 247 filings; by 2024, the last year the dataset treats as complete, annual filings had fallen to 143 from 210 in 2021. Read 2025 and 2026 figures as provisional given the roughly 18-month gap between filing and publication.
C12N and C07H each touch roughly half the record set, reflecting the field's centre of gravity in solid-phase chemical synthesis and nucleic-acid chemistry. C12P, covering fermentation and enzymatic synthesis approaches to oligonucleotide production, sits far lower at 10.1%, marking it as the thinner-claimed alternative route.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to oligonucleotide manufacturing process, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Sirna Therapeutics, Inc. | MCSWIGGEN JAMES | 127 |
| MCSWIGGEN JAMES | BEIGELMAN LEONID | 106 |
| Sirna Therapeutics, Inc. | BEIGELMAN LEONID | 74 |
| MCSWIGGEN JAMES | USMAN NASSIM | 40 |
| Wave Life Sciences Ltd | VARGEESE CHANDRA | 38 |
| Sirna Therapeutics, Inc. | VARGEESE CHANDRA | 35 |
| Corixa Corp | WANG TONGTONG | 29 |
| Corixa Corp | HARLOCKER SUSAN L | 29 |
Co-filing is limited and concentrated: of 10 identified co-assignee pairs, the strongest links run through a small cluster of individual inventors and their affiliated corporate assignees, rather than broad industry consortia.
The assignee ranking runs 100 companies deep, but a small group at the top account for over a third of all records. Recent-year momentum, however, shows even leading assignees pulling back or going quiet.
The leading assignee's 886 records are more than four times the fifth-place total of 209, and roughly seven times tenth place at 124. That gap suggests a portfolio built over many years of continuation filing rather than one recent surge.
Among assignees with visible recent-year activity, filings are falling rather than accelerating: one tracked filer dropped 63% year over year to 9 filings, while several historically significant assignees show zero filings in the latest year.
Below the top ten, the ranked list continues for 100 companies total, with combined share falling well short of half the field even at ten deep (36.2%). New entrants are not filing into empty space, but they are not filing into a duopoly either.
| Assignee | Recent year | YoY |
|---|---|---|
| Wave Life Sciences Ltd | 9 | -63% |
| Twist Bioscience Corp | 2 | 0% |
| Sirna Therapeutics, Inc. | 0 | — |
| Corixa Corp | 0 | — |
| Ionis Pharmaceuticals, Inc. | 0 | — |
| Nanosphere, Inc. | 0 | — |
| MCSWIGGEN JAMES | 0 | — |
| Affymetrix, Inc. | 0 | — |
The dataset points to specific next steps depending on whether you are drafting, licensing, or scouting for freedom to operate.
With one assignee holding 886 records against a fifth-place total of 209, any new coupling-efficiency or detritylation claim should be checked against that portfolio's continuation chain before drafting.
Run a freedom-to-operate scan in EurekaC12P's 10.1% share against C12N's 49.2% and C07H's 45.2% suggests fermentation and enzymatic routes carry materially less claim density than chemical synthesis paths.
Map white space in EurekaSeveral historically significant filers show zero filings in the latest year, which can mean a licensing opportunity or a strategic pivot worth confirming directly.
Track assignee activity in EurekaOne assignee leads the ranked list with 886 records, well ahead of fifth place at 209 and tenth place at 124. The top five assignees combined hold 27.3% of all 8,130 records in scope, and the top ten hold 36.2%. That still leaves the majority of the field spread across a ranking that runs 100 companies deep, so leadership at the top does not translate into control of the whole space.
Filing peaked in 2018 at 247 records and has since eased; from 2021 (210) to 2024 (143) filings fell 32%, and 2024 is the most recent year the dataset treats as complete. Figures for 2025 and 2026 are still filling in because publication typically lags filing by around 18 months, so they should not yet be read as a continuing decline. The honest read is a cooling trend through the mid-2020s rather than a collapse.
Chemical synthesis approaches, captured mainly under C12N and C07H, appear in roughly half of all 8,130 records (49.2% and 45.2% respectively), reflecting decades of phosphoramidite and solid-support chemistry claims. Enzymatic and fermentation-based routes, classified under C12P, appear in only 10.1% of records. That gap indicates enzymatic synthesis is a comparatively under-claimed manufacturing route rather than a mature, heavily contested one.
US20090317873A1, assigned to DNA Twopointo, Inc. and published in December 2009, covers methods for synthesizing oligonucleotides at greater than 99.5% coupling efficiency, purification methods, synthesis instrumentation configurations, and design/assembly methods for building longer polynucleotides from shorter synthesized fragments with codon-bias-aware design. It is one of the representative records in this dataset for high-efficiency coupling methodology. Anyone drafting new coupling-efficiency claims should read its specification closely, since its scope touches both the chemistry and the assembly workflow around it.
The United States receives the largest share of filings in this dataset at 2,578 records, followed by the EPO at 1,280 and WIPO/PCT filings at 1,251. Australia (753), Canada (447) and Austria (306) follow at meaningfully lower volumes. A filing strategy focused only on the US and Europe would still miss a substantial share of the activity captured through PCT-route filings, which often precede national-phase entry elsewhere.
Go past this page: query the whole oligonucleotide manufacturing process corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.
Help us improve
Something wrong, out of date, or missing on this page? Tell us and it goes straight to the team that maintains it.
This page